MPMikkel Hasse Pedersen

Mikkel Hasse Pedersen

*This is an algorithmically generated author record based on publicly available information.

Mikkel Hasse Pedersen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study

    by Maria João Fonseca, Stanislava Bratković, Mikkel Pedersen, Mathilde Kany, Triantafyllos Pliakas, Rachel Reeves, Alen Marijam, Elisa Turriani, Nikoline Vestergaard Dich, Yunus Çolak, et al.

    Respiratory syncytial virus (RSV) is, like influenza, one of the most common causes of severe acute respiratory infections (ARIs) in adults; however, its incidence across different risk and age groups is unknown. We estimated the incidence of registered ARIs in Danish adults, focusing on RSV and contextualizing with influenza. We conducted a nationwide cohort study in Denmark, including all adults aged ≥18 y with a registered ARI, during the 2011/12 to 2022/23 seasons. We estimated the incidence (per 100,000 person-years) of ARI overall and ARI attributable to RSV or influenza, overall and stratified by sex, age, and comorbidity. We identified 962,858 ARIs, of which 10,437 (1.1%) were attributed to RSV and 62,869 (6.5%) to influenza. The ARI incidence increased over time (range: 1,272-2,144), including a rise in RSV incidence (range: 0.2-91.6), while influenza incidence fluctuated (range: 6.7-322.0). In the 2022/23 season, RSV incidence was higher among females, older adults (198.7 in ≥60-y-olds, and 303.2 in ≥75-y-olds), and those with comorbidities, especially hematologic disease (868.6) and chronic obstructive pulmonary disease (679.5). Although influenza incidence was generally higher than RSV, the incidences were comparable for older adults and those with comorbidities. In conclusion, RSV is an important cause of ARIs among adults, comparable to influenza, particularly in older adults and those with comorbidities. These findings underscore the substantial burden of RSV that is relevant for public health planning and clinical decision-making, particularly given the recent approval of three highly effective RSV vaccines.


  • Open Access

    Economic benefits of remimazolam compared to midazolam and propofol for procedural sedation in colonoscopies and bronchoscopies

    by Mikkel H. Pedersen, Anne Danø, Ebbe Englev, Lisbeth Kattenhøj, Emma Munk

    Sedation is common practice in endoscopic procedures to suppress a patient’s level of consciousness while maintaining the cardio-respiratory function. Midazolam and propofol are the sedatives most ...


  • Open Access

    Impact of new cancer medicine – real-world evidence from Danish register study of lung cancer patients

    by Jan H. Rudolfsen, Mads D. Hjortsø, Mikkel H. Pedersen, Trine Pilgaard, Mette Pøhl

    Lung cancer (LC) is the leading cause of cancer deaths worldwide. Several new treatments have become available in recent decades, but little research exists on the impact of these on productivity, ...


  • Open Access

    Administration and patient-incurred costs associated with opioid agonist treatment in Norway

    by Mikkel H. Pedersen, Anne Danø, Carl Gibbons, Rasmus Jensen

    Opioid use disorder is associated with high rates of mortality and has become an escalating global health issue. Opioid agonist treatment (OAT) with oral methadone or daily sublingual buprenorphine...


  • Open Access

    The prevalence of comorbidities in Danish patients with obesity – A Danish register‐based study based on data from 2002 to 2018

    by Mikkel H. Pedersen, Mette Bøgelund, Carsten Dirksen, Pierre Johansen, Nils B. Jørgensen, Sten Madsbad, Ulrik H. Pantin

    Summary: We used the Danish National Health Registers to conduct a study on the prevalence of obesity‐related comorbidities in Danish citizens who have been diagnosed with obesity at a Danish hospital. This was a retrospective observational study with a population comprising all Danish citizens (≥18 years) who have been registered with a specific obesity class diagnosis in the Danish National Patient Register between 2002 and 2018. A total of 86 980 persons with hospital‐diagnosed obesity were included in the study population. To investigate how the risk of having comorbidities varies with the degree of obesity, we applied adjusted logistic regression to estimate the odds ratio of having one of the following predefined comorbidities for people with a BMI in obesity classes II and III compared with people with a BMI in obesity class I: type 2 diabetes, ischaemic heart disease, non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease, hip and knee osteoarthritis, obstructive sleep apnoea and asthma. Comorbidities were defined from ICD‐10 diagnosis codes and prescription medication utilization. The odds ratio for obstructive sleep apnoea (OR 1.86 and OR 3.0), type 2 diabetes (OR 1.68 and OR 2.26), hip and knee osteoarthritis (OR 1.29 and OR 1.54) and asthma (OR1.13 and OR 1.25) increased significantly with obesity class (obesity class II relative to I and III relative to I, respectively). The odds ratio of having had at least one comorbidity was estimated to be 1.52 for people with a BMI in obesity class II and 2.10 for people with a BMI in obesity class III compared with people in obesity class I. The risk of obstructive sleep apnoea, type 2 diabetes, hip and knee osteoarthritis, and asthma increased significantly with increasing BMI, highlighting the importance of preventing further weight gain even in individuals who are already living with obesity.


  • Open Access

    The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data

    by Maria Spanggaard, Mette Bøgelund, Carsten Dirksen, Nils Bruun Jørgensen, Steen Madsbad, Ulrik Haagen Panton, Mikkel H. Pedersen, Signe Baattrup Reitzel, Pierre Johansen

    The Danish national health registers were used to investigate the economic burden of obesity, associated costs of comorbidities and a breakdown into direct and indirect costs.The study population c...


  • Open Access

    Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

    by Mette Bøgelund, Ana Rosado Ingelmo, Jose María Ausín Ruiz, Adolfo Galán Vivó, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager, Mark Aagren

    Background: This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy‐tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective.Methods: A discrete choice experiment (DCE) consisting of two blocks with eight choice sets in each was constructed to elicit the preferences for AIT. Three attributes were included in the DCE for the mode of administration, including the frequency of administration, the risk of systemic reactions and the co‐payment. Adults and caregivers of children with moderate to severe allergic rhinitis (AR) were included if they were not currently receiving or had not previously received AIT.Results: In total, 587 adults and 613 caregivers started the survey. Of those, 579 adults and 611 caregivers completed the survey and were included in the study. Both adults and caregivers had a significant preference for tablets compared with both monthly and weekly injections (p ≤ 0.0001). Furthermore, the respondents showed a significant preference for reducing the risk of systemic reactions. Subgroup analyses showed that caregivers of polyallergic children and female caregivers were significantly less price sensitive when choosing their preferred treatment.Conclusion: Our study demonstrated that both adults with AR and caregivers of children with AR prefer daily SLIT‐tablets to SCIT with either a weekly or monthly dose schedule.


  • Open Access

    The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment

    by Mette Bøgelund, Nils B. Jørgensen, Sten Madsbad, Maria Spanggaard, Ulrik H. Panton, Mikkel H. Pedersen, Pierre Johansen

    Purpose: We aimed to estimate the total cost of bariatric surgery in Denmark. Materials and Methods: The study population included all Danish citizens ≥ 18 years who had received bariatric surgery, identified in the Danish National Patient Register in the period from 2002 to 2018. Patients who had received bariatric surgery were matched with three controls on gender, year of birth, and region of residence. A difference-in-difference approach was used to estimate the healthcare costs attributable to bariatric surgery from 3 years before to 5 years after surgery. Results: Total healthcare costs for cases receiving bariatric surgery during the first 5 years following surgery amounted to EUR 32,899, and EUR 16,651 for their matched controls. Thereby, the difference in total healthcare costs (EUR 16,248) between persons receiving bariatric surgery and their matched controls was 2.2 times the DRG rate for the surgery itself (EUR 7387). Moreover, the results suggest that receiving bariatric surgery led to a total increase in gross earnings of EUR 5970 (5%) and a total reduction in receipt of transfer payments of EUR 4488 (12%) in the period up until 5 years after surgery. Conclusion: The results showed a significant and persistent increase in healthcare costs for people with obesity receiving bariatric surgery during the first 5 years after surgery. We also found that bariatric surgery was associated with increased attachment to the labor market. Graphical


  • Open Access

    Preference for Immunotherapy with Tablets by People with Allergic Rhinitis

    by Mike Tankersley, Tonya Winders, Mark Aagren, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager, Mette Bøgelund

    Background: People with allergic rhinitis (AR) who are not controlled on conventional therapy can be treated using allergy immunotherapy (AIT) administered as tablets, injections or drops. In the US, the use of sublingual immunotherapy as tablets (SLIT-tablets) is limited in comparison to subcutaneous immunotherapy (SCIT). Objective: This study investigated patients’ preference for SLIT-tablets vs monthly or weekly SCIT from a US patient perspective. Methods: We carried out a discrete choice experiment (DCE) consisting of two blocks with eight choice sets. Adults and caregivers of children with moderate-to-severe AR were included if they had not previously or were not currently receiving AIT. Three attributes were included in the design: the mode and frequency of administration, the risk of systemic reactions and the co-payment. Results: A total of 724 adults with AR and 665 caregivers of children with AR were included in the study. Both adults and caregivers had a significant preference for SLIT-tablets compared with both weekly and monthly injections and for less risk of anaphylactic shock. Caregivers were more risk-averse than adults when choosing their treatment, and the younger the child, the more risk-averse the caregiver. The preference for SLIT-tablets was found for both monoallergic and polyallergic adults and caregivers of monoallergic and polyallergic children. Respondents not wanting AIT for free were more risk-averse than those indicating that they wanted AIT for free. Conclusion: Our findings suggest that SLIT-tablets is the preferred route of administration for AIT among adults and caregivers of children with AR.


  • Open Access

    Subcutaneous immunotherapy takes more than the time in the clinic

    by Mike Tankersley, Tonya Winders, Mark Aagren, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager, Mette Bøgelund

    The aim of this study was to investigate the time use and both direct and indirect costs associated with subcutaneous immunotherapy (SCIT) for adults with allergic rhinitis (AR) and caregivers of children with AR in the US. We conducted a survey to assess the retrospective time use and direct costs of SCIT. The populations surveyed included adults and caregivers of children (aged 5-17) with symptomatic AR of moderate or higher severity who are currently receiving or have previously started allergy immunotherapy (AIT). The retrospectively collected, self-reported time consumption and direct costs per clinic visit when receiving SCIT were assessed as well as the productivity loss associated with SCIT. Data were analyzed using univariate descriptive statistics. The study included 106 adults with AR and 191 caregivers of children with AR. We found that the median time spent per visit to the clinic was 50 minutes for both groups, including travel time and time at the clinic. The direct costs related to each visit included parking fees, road tolls and other costs. Adults spent $10 on parking, $9 on tolls and $10 on other costs. Finally, a median 4 hours of work was missed for both the adult patients and the adults accompanying a child. We found that SCIT is associated with substantial direct patient costs and productivity loss for both adults with AR and caregivers of children with AR.